Leal T, et al. Identifying resistance to immune checkpoint inhibitors by screening for PD-L1 and MHC I expression on CTCS in pts with NSCLC. IASLC 2018; abstract P3.04-08.
Olaparib plus bevacizumab bij ovariumcarcinoom: definitieve OS-resultaten van PAOLA-1
aug 2023 | Gynaecologische oncologie